NCT03982225View on ClinicalTrials.gov

Evaluate the Efficacy and Safety of Polyene Phosphatidylcholine Injection (AYP-101) for the Reduction of Submental Fat

PHASE2CompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

October 21, 2022

Study Completion Date

October 21, 2022

Conditions
Moderate or Severe Submental Fullness
Interventions
DRUG

Polyene phosphatidylcholine injection

Formulated as an injectable solution containing Polyene Phosphatidylcholine at two concentration of 25 mg/mL and 50 mg/mL.

DRUG

Placebo

Phosphate buffered saline placebo for injection

Trial Locations (4)

13620

Seoul National University Bundang Hospital, Seongnam-si

03722

Yonsei University Health System, Severance Hospital, Seoul

05505

Asan Medical Center, Seoul

06273

Yonsei University Health System, Gangnam Severance Hospital, Seoul

All Listed Sponsors
lead

AMIpharm Co., Ltd.

INDUSTRY

NCT03982225 - Evaluate the Efficacy and Safety of Polyene Phosphatidylcholine Injection (AYP-101) for the Reduction of Submental Fat | Biotech Hunter | Biotech Hunter